Atamyo Therapeutics has secured approval from AIFA and ANSM to conduct a Phase Ib clinical trial for ATA-200 targeting limb-girdle muscular dystrophy Type 2C/R5.

The trial is set to commence in Q3 2024, aiming to evaluate the safety and efficacy of ATA-200 in paediatric patients.

Beyond ATA-200, Atamyo is advancing trials for ATA-100 for LGMD2I/R9 and conducting IND-enabling studies for LGMD2A/R1.

Atamyo's CEO, Stéphane Degove, remains positive about the prospects of ATA-200 and ATA-100 in treating various forms of limb-girdle muscular dystrophies.

These advances mark a significant step in gene therapy and neurology/psychiatric medicine, especially in the European region.